Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Mar 21, 2025 · CIK: 1581178
Sentiment: neutral
Topics: filing, press-release, foreign-private-issuer
TL;DR
Eupraxia Pharma dropped a 6-K with a press release on March 20th. Check it out.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on March 21, 2025, reporting on activities for the month of March 2025. The filing includes Exhibit 99.1, a press release dated March 20, 2025. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' activities and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate indication of significant financial or operational changes.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- March 20, 2025 (date) — Press Release Date
- March 21, 2025 (date) — Filing Date
- Alex Rothwell (person) — Signatory for Eupraxia Pharmaceuticals Inc.
- Victoria, British Columbia, Canada (location) — Principal Executive Office Location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public pursuant to the laws of their home country, or that they have filed or will file with a stock exchange on which they are traded.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated March 20, 2025, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Which form does Eupraxia Pharmaceuticals Inc. indicate it will file annually?
Eupraxia Pharmaceuticals Inc. indicates it will file annually under Form 40-F.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Alex Rothwell signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 21, 2025 by Alex Rothwell regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).